StageZero Life Sciences Stock Forecast, Price & News

StageZero Life Sciences (OTCMKTS:GNWSF) Frequently Asked Questions

Is StageZero Life Sciences a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for StageZero Life Sciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" StageZero Life Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNWSF, but not buy additional shares or sell existing shares.
View analyst ratings for StageZero Life Sciences or view top-rated stocks.

What stocks does MarketBeat like better than StageZero Life Sciences?

Wall Street analysts have given StageZero Life Sciences a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but StageZero Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has StageZero Life Sciences' stock price been impacted by COVID-19?

StageZero Life Sciences' stock was trading at $0.0266 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GNWSF stock has increased by 1,027.8% and is now trading at $0.30.
View which stocks have been most impacted by COVID-19.

Who are StageZero Life Sciences' key executives?

StageZero Life Sciences' management team includes the following people:

• Mr. James R. Howard-Tripp, Exec. Chairman & CEO
• Mr. Carl Solomon, Interim Chief Financial Officer
• Prof. Choong-Chin Liew, Co-Founder
• Mr. Warren Whitehead C.M.A., Chief Accountant (Age 69)
• Mr. David Suria, Sr. Scientist

Who are some of StageZero Life Sciences' key competitors?

Some companies that are related to StageZero Life Sciences include ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), ARCA biopharma (ABIO), StageZero Life Sciences (SZLSF), Global WholeHealth Partners (GWHP), StageZero Life Sciences (GNWSD), Fuse Science (DROP), BG Medicine (BGMD), FluoroPharma Medical (FPMI), Hemagen Diagnostics (HMGN) and Response Genetics (RGDXQ).
View all of GNWSF's competitors.

What is StageZero Life Sciences' stock symbol?

StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is StageZero Life Sciences' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.30.

How much money does StageZero Life Sciences make?

StageZero Life Sciences has a market capitalization of $18.90 million and generates $4.15 million in revenue each year.

How many employees does StageZero Life Sciences have?

StageZero Life Sciences employs 51 workers across the globe.

What is StageZero Life Sciences' official website?

The official website for StageZero Life Sciences is www.stagezerolifesciences.com.

Where are StageZero Life Sciences' headquarters?

StageZero Life Sciences is headquartered at 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2.

How can I contact StageZero Life Sciences?

StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected].